Drug intelligence / Profile preview

HP-TAT

Development stage: Preclinical
Lead developer: NanoPharmaceuticals
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Intravitreal, Ophthalmic

Overview

HP-TAT is a preclinical-stage nanoparticle therapeutic being developed by NanoPharmaceuticals for the treatment of ophthalmic disorders, including macular degeneration, diabetic retinopathy, and other proliferative angiopathies. The drug is designed to target thyrointegrin alpha-V/beta-3 receptors, which are overexpressed in active neovascularization and proliferative ocular tissues. By antagonizing these receptors, HP-TAT aims to inhibit pathological angiogenesis and vascular leakage in the retina, offering a potential treatment for progressive vision loss associated with retinal vascular diseases.

Targets

αVβ1 (Integrin alpha-V beta-1)αVβ6 (Integrin αVβ6)αVβ3 (Integrin αVβ3)GPIIb/IIIa (Integrin alpha-IIb/beta-3)

Beyond the preview

Go deeper on HP-TAT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HP-TAT.

Explore the full profile